Clinical trials: Osteoarthritis (Knee / Hip)
Osteoarthritis, Pain
Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of fulranumab as Monotherapy compared with placebo in participants with signs and symptoms of osteoarthritis of the hip or knee that are not…
- Trial name
- NCT02289716
- Testing
- Fulranumab 1 mg, Fulranumab 3 mg
- Where
- 28 sites in United States, Belgium and 6 more
- Volunteers
- 41 people
- Sponsor
- Janssen Research & Development, LLC
Osteoarthritis, Hip, Arthritis
A Clinical Investigation of the M2a-Magnum™ Hip System
The purpose of this prospective clinical data collection is to document the performance and clinical outcomes of the M2a-Magnum™ Hip System
- Conditions
- Osteoarthritis, Hip, Arthritis, Rheumatoid Arthritis, Joint Disease
- Trial name
- NCT00698347
- Testing
- M2a-Magnum™ Hip System
- Volunteers
- 249 people
- Sponsor
- Biomet Orthopedics, LLC
Osteoarthritis, Knee, Osteoarthritis, Hip
To Assess the Patients' Ability to Self-Administer Fasinumab
The primary objective is to demonstrate that the auto-injector(AI) is suitable to be used to administer fasinumab at home by patients or their caregivers, as measured by collecting 12 weeks of actual-use data on the technical…
- Trial name
- FACT DEVICE (NCT03491904)
- Testing
- Fasinumab AI, Fasinumab PFS
- Where
- 23 sites in United States
- Volunteers
- 100 people
- Sponsor
- Regeneron Pharmaceuticals
Osteoarthritis
Prospective Multicenter Non-interventional Study in Patients With Knee or Hip Osteoarthritis Having a Theraflex Treatment
The main purpose of this study is to evaluate how a long-term treatment with Theraflex during 64 weeks affects pain intensity in the affected knee or hip joint, the activity in daily living, the quality of life and patient…
- Trial name
- NCT03330288
- Testing
- Theraflex, BAY 874017
- Where
- 2 sites in Russia
- Volunteers
- 1,102 people
- Sponsor
- Bayer
Osteoarthritis, Knee, Osteoarthritis, Hip
Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip
The objective of this exploratory study is to evaluate the cellular and connective tissue composition of joints from patients with Osteoarthritis (OA) who have been treated with fasinumab, compared with those treated with placebo…
- Trial name
- NCT03949673
- Testing
- Fasinumab, Naproxen, Diclofenac
- Where
- 15 sites in United States, Poland and 1 more
- Volunteers
- 23 people
- Sponsor
- Regeneron Pharmaceuticals
Osteoarthritis, Knee, Osteoarthritis, Hip
Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee
The primary objective of the study is to evaluate the effect of fasinumab compared to placebo on peripheral nerves in participants with pain due to Osteoarthritis (OA) of the hip or knee.
- Trial name
- NCT03691974
- Testing
- Fasinumab
- Where
- 47 sites in United States, Poland and 1 more
- Volunteers
- 180 people
- Sponsor
- Regeneron Pharmaceuticals
Osteoarthritis
Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED)
To compare the safety and tolerability of etoricoxib and diclofenac sodium in the treatment of osteoarthritis of the knee or hip during a six week period.
- Trial name
- NCT00542087
- Testing
- MK0663, etoricoxib / Duration of Treatment: 6 Weeks, Comparator: diclofenac sodium / Duration of Treatment: 6 Weeks
- Volunteers
- 516 people
- Sponsor
- Organon and Co
Osteoarthritis
An Effectiveness and Safety Study of Two Doses of Acetaminophen Extended Release Caplets in the Treatment of Osteoarthritis of the Hip or Knee
The purpose of this study is to determine the safety and effectiveness of 650 mg and 1300 mg acetaminophen extended release given three times a day for the relief of signs and symptoms of osteoarthritis of the hip or knee for a…
- Trial name
- NCT00240786
- Testing
- acetaminophen extended release
- Volunteers
- 483 people
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Osteoarthritis
Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis
Study to compare the percentage of treatment successes or failures in patients randomized to meloxicam 7.5 mg vs. usual care prescription NSAIDs.
- Trial name
- NCT02183064
- Testing
- Meloxicam, NSAID
- Volunteers
- 1,309 people
- Sponsor
- Boehringer Ingelheim
Joint Osteoarthritis, Knee Osteoarthristis
Clinical Evaluation of TrHCROSS® for Different Joints
This post-market clinical investigation is designed to evaluate the safety and effectiveness of TrHCROSS®, a CE-marked cross-linked hyaluronic acid viscosupplement, in patients with mild to moderate osteoarthritis of the knee…
- Conditions
- Joint Osteoarthritis, Knee Osteoarthristis, Hip Ostearthritis, Shoulder Osteoarthritis
- Trial name
- NCT07870031
- Testing
- TrHCROSS®, Monovisc
- Volunteers
- 150 people
- Sponsor
- i+Med S.Coop.
Osteoarthritis
Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly
The primary objective is to compare buprenorphine transdermal delivery system (BTDS) with standard- treatment in subjects with osteoarthritis (OA).
- Trial name
- NCT00324038
- Testing
- Buprenorphine, Codeine paracetamol
- Where
- United Kingdom
- Volunteers
- 219 people
- Sponsor
- Napp Pharmaceuticals Limited
Pain, Nausea
A Multi-Center Actual-Use Study on the Safety of CL 108 for the Treatment of Moderate to Severe Acute Pain Associated With Osteoarthritis of the Knee or Hip
The purpose of CLCT-006, a multi-center open-label study, is to evaluate the safety of CL-108 (hydrocodone 7.5 mg/APAP 325 mg, promethazine 12.5 mg) for the treatment of moderate to severe acute pain ("flare") associated with…
- Conditions
- Pain, Nausea, Vomiting
- Trial name
- NCT02462850
- Testing
- CL-108
- Where
- United States
- Volunteers
- 178 people
- Sponsor
- Charleston Laboratories, Inc
Osteoarthritis
Use of Autologous Adipose-Derived Stromal Vascular Fraction To Treat Osteoarthritis of Hip, Knee, Ankle, and Thumb Joints
This study will examine the safety and efficacy of autologous adipose-derived stromal vascular fraction (SVF) cells for treatment of hip, knee and thumb osteoarthritis (OA); monitoring adverse events and measuring pain, function…
- Trial name
- NCT03166410
- Testing
- Cell injection
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Texas Plastic Surgery
Osteoarthritis, Pain
Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of fulranumab as Monotherapy compared with placebo in participants with signs and symptoms of osteoarthritis of the hip or knee that are not…
- Trial name
- NCT02336698
- Testing
- Fulranumab 1 mg, Fulranumab 3 mg
- Where
- 32 sites in United States, Poland and 2 more
- Volunteers
- 18 people
- Sponsor
- Janssen Research & Development, LLC
Osteoarthritis, Hip, Osteoarthritis, Knee
A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone HCL for Treatment of Patients With Osteoarthritis
The purpose of this study was to compare the analgesic (a drug that relieves pain) effectiveness and safety of OROS hydromorphone HCI (slow release) 8 mg and 16 mg to placebo (no drug) in patients with osteoarthritis (OA).
- Trial name
- NCT00411164
- Testing
- OROS hydromorphone HCI (slow release)
- Volunteers
- 990 people, healthy volunteers welcome
- Sponsor
- Alza Corporation, DE, USA
Osteoarthritis, Osteoarthritis, Knee
A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women
The purpose of this study is to evaluate the efficacy of hydrolyzed collagen in osteoarthritis.
- Conditions
- Osteoarthritis, Osteoarthritis, Knee, Osteoarthritis, Hip
- Trial name
- NCT05070871
- Testing
- Hydrolyzed Collagen, CalGo
- Where
- 3 sites in Norway
- Volunteers
- 98 people
- Sponsor
- Hofseth Biocare ASA
Osteoarthritis, Hip, Osteoarthritis, Knee
A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain
The purpose of this study is to evaluate the safety profile of tapentadol (CG5503) PR at doses of 100 mg - 250 mg administered twice daily over a maximum one year period to patients with at least a 3-month history of low back…
- Conditions
- Osteoarthritis, Hip, Osteoarthritis, Knee, Lower Back Pain, Pain
- Trial name
- NCT00361504
- Testing
- Oxycodone CR, Tapentadol (CG5503) ER
- Where
- 52 sites in United States, Canada
- Volunteers
- 1,123 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Osteoarthritis of the Hip or Knee
Dexibuprofen 400 mg Sachet Versus Ibuprofen 400 mg Sachet in Patients With Osteoarthritis of the Hip or Knee
Medical condition under investigation: Osteoarthritis of the hip or knee Number of patients planned: 480 adult patients Main objective: To evaluate and compare the tolerability profile of Dexibuprofen Gebro 400 mg powder for oral…
- Trial name
- NCT01066676
- Testing
- Dexibuprofen, Ibuprofen
- Where
- 2 sites in Austria
- Volunteers
- 482 people
- Sponsor
- Gebro Pharma GmbH
Osteoarthritis, Osteoarthritis, Hip
A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain
The purpose of this study is to compare the safety and effectiveness of different doses of JNJ-42160443 with placebo in the treatment of chronic, moderate to severe knee or hip pain in patients with a diagnosis of osteoarthritis.
- Conditions
- Osteoarthritis, Osteoarthritis, Hip, Osteoarthritis, Knee, Pain
- Trial name
- NCT00973141
- Testing
- JNJ-42160443
- Where
- 77 sites in United States, Canada and 2 more
- Volunteers
- 467 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Osteoarthritis, Knee, Osteoarthritis, Hip
Phase II Study of CG100649 for Primary Osteoarthritis in Male Subjects
The primary objective of this study is to evaluate the safety and efficacy of 3 loading and maintenance dose levels of CG100649 administered for 21 days in the treatment of osteoarthritis pain.
- Trial name
- NCT00530452
- Testing
- CG100649, Silicified microcrystalline cellulose + talc
- Where
- Germany
- Volunteers
- 240 people
- Sponsor
- CrystalGenomics, Inc.